Skip to main content
. 2020 May 9;2020:9512793. doi: 10.1155/2020/9512793

Figure 1.

Figure 1

miR-520h expression promotes drug resistance in human breast cancer cells. (a) Viability of MCF-7/Vec and MCF-7/miR-520h cells after exposure to paclitaxel. (b) Viability of MCF-7 cells with miR-520h inhibition after treatment with increasing concentrations of paclitaxel. (c) The clonogenic ability of MCF-7/Vec and MCF-7/miR-520h cells after treatment with various concentrations of paclitaxel. (d) The clonogenic ability of MCF-7 cells with miR-520h inhibition after treatment with various concentrations of paclitaxel. (e) MCF-7 cells were transfected with vector or miR-520h and treated with 5 nM of paclitaxel for 24 h and then the apoptosis assayed by flow cytometry analysis. (f) MCF-7 cells were transfected with control or miR-520h inhibitor and treated with 5 nM of paclitaxel for 24 h and then the apoptosis assayed by flow cytometry analysis. Results were collected from three independent experiments, with triplicate repeats for each experiment. ∗P < 0.05, ∗∗P < 0.01.